Treating psoriasis by targeting its susceptibility gene Rel

Clin Immunol. 2016 Apr:165:47-54. doi: 10.1016/j.clim.2016.03.009. Epub 2016 Mar 16.

Abstract

Psoriasis is a chronic inflammatory disorder of the skin. Accumulating evidence indicates that the Rel gene, a member of the NF-κB family, is a risk factor for the disease. We sought to investigate whether psoriasis can be prevented by directly targeting the Rel gene transcript, i.e., the c-Rel mRNA. Using chemically-modified c-Rel specific siRNA (siRel) and poly(ethylene glycol)-b-poly(l-lysine)-b-poly(l-leucine) (PEG-PLL-PLLeu) micelles, we successfully knocked down the expression of c-Rel, and showed that the expression of cytokine IL-23, a direct target of c-Rel that can drive the development of IL-17-producing T cells, was markedly inhibited. More importantly, treating mice with siRel not only prevented but also ameliorated imiquimod (IMQ)-induced psoriasis. Mechanistic studies showed that siRel treatment down-regulated the expression of multiple inflammatory cytokines. Taken together, these results indicate that the susceptibility gene Rel can be targeted to treat and prevent psoriasis.

Keywords: IL-17A; PEG-PLL-PLLeu micelles; Psoriasis; c-Rel; siRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Delivery Systems*
  • Genes, rel / genetics*
  • Genetic Predisposition to Disease*
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Psoriasis / drug therapy*
  • Psoriasis / genetics*
  • RNA, Small Interfering / therapeutic use*
  • RNA-Induced Silencing Complex / therapeutic use
  • Real-Time Polymerase Chain Reaction

Substances

  • RNA, Small Interfering
  • RNA-Induced Silencing Complex